DDR1 and neoplasm: In this context, the efficacy of an anti-DDR1 antibody to the DDR1 extracellular domain in collagen fiber rearrangement, enhancing T cell infiltration [117], led to the development of DDR1-DX8951, an antibody–drug conjugate that includes an anti-DDR1 mAb in combination with the immune checkpoint inhibitor, pembrolizumab, which revealed to be efficacy in the inhibition tumor growth and metastasis and in improving the immunosuppressive TME in preclinical models of TNBC [118].